How do tissue banks validate regulatory compliance? Tissue bank compliance is not one certificate. It is four separate layers that each produce different paperwork. This guide walks through federal registration, the quality system behind Current Good Tissue Practice, lot release testing, and the accreditation bodies that state legislatures started writing into statute in 2025 and 2026.
TLDR: Compliance at a tissue bank is four stacked layers. The establishment registers and lists its products with FDA under 21 CFR Part 1271. Current Good Tissue Practice, in Subpart D, supplies the working quality system covering donor eligibility, facilities, equipment, reagents, process controls, labeling, storage, records, and complaints. Release testing checks each individual lot for sterility, endotoxin, and mycoplasma. Third-party accreditation, once voluntary, now appears by name in Florida, Georgia, and Tennessee law. None of this guarantees eligibility, access, or clinical benefit, and banking adipose tissue is not a treatment.
Important Disclaimer: Save My Fat is a tissue preservation connector and does not provide FDA-approved treatments or cures. Save My Fat does not collect, process, store, or test tissue itself, and it does not guarantee eligibility, access, or clinical benefit from any facility or standard described below. Adipose tissue and stromal vascular fraction remain investigational and are not FDA approved. This article is provided for educational purposes only, and readers should consult their own licensed healthcare professionals before making any decision about tissue banking.
Ask a tissue bank whether it is compliant and you usually get a one-line answer. We are FDA registered. That sentence is true at most legitimate facilities, and it describes about a quarter of what compliance involves.
Registration is a filing. It says nothing about whether the freezers are qualified, whether reagents trace back to a lot number, or whether last month’s sterility results cleared before product shipped.
The rest lives in documents patients almost never see: standard operating procedures, environmental monitoring logs, equipment calibration records, and lot-specific certificates of analysis. Here is what sits behind that one-line answer.
Tissue Bank Compliance: Four Layers, Not One
Compliance is not a single test a facility passes. It is four independent systems producing four kinds of evidence, so HCT/P compliance verification means checking four separate trails rather than one document. The table below maps the structure before we take each layer apart.
| Layer | What it governs | Where the requirement sits | Evidence it produces |
|---|---|---|---|
| Establishment registration and listing | That FDA knows the facility exists and which HCT/Ps it handles | 21 CFR Part 1271 | A public registration record and a current product listing |
| Current Good Tissue Practice | Donor eligibility, facilities and environmental control, equipment, supplies and reagents, process controls, labeling, storage, records, complaint handling | Part 1271 Subpart D | Procedures, validation and monitoring records, training files, deviation reports |
| Release testing | Whether one specific lot meets its written specification before it leaves | USP chapter 71, tied to 21 CFR 610.12, plus the bank’s own written specification | A lot-specific certificate of analysis |
| Third-party accreditation | Independent audit against a published standard | AATB, AABB, WMDA, NMDP, and FACT, now named in state statutes | A current certificate showing scope, effective date, and expiration |
Read the last column first. A facility that can produce all four columns on request is telling a very different story than one that can produce only the first.
Layer One: Registration and Listing Tell You Less Than You Think
The tissue bank FDA compliance process starts here. An establishment that recovers, processes, stores, labels, packages, or distributes human cells and tissues registers with FDA and lists what it handles under 21 CFR Part 1271. FDA’s tissue products program page is the public entry point to that framework.
Here is the part that gets misread constantly. Registration is not approval, not clearance, and not endorsement. FDA does not review a product before an establishment registers, and the filing carries no finding that anything the facility makes is safe or effective. A closer look at FDA establishment registration covers what that record does and does not mean.
Registration still matters, because state law now leans on it directly. Tennessee splits the duty by product type: allogeneic material must come from a facility that gives the physician proof of FDA registration, while autologous material must come from a facility holding a CLIA certificate of compliance.
Layer Two: Current Good Tissue Practice Is the Actual Quality System
Subpart D of Part 1271 is where compliance stops being a filing and becomes daily work. Current Good Tissue Practice controls the steps where tissue could be contaminated, mixed up, degraded, or mishandled, and it demands a written record at each one.
Donor eligibility comes first, meaning screening and testing performed and documented before material moves forward. Facilities and environmental control follow, covering the physical space, air handling, cleaning, and the monitoring data that proves those controls held. Equipment must be qualified, calibrated, and maintained on schedule, with records to show it.
Supplies and reagents carry their own controls, because a reagent lot with no traceability breaks the chain behind it. Process controls require written procedures plus validation showing the process does what it claims. Labeling controls stop mix-ups between samples. Storage controls set temperature limits and monitor them continuously. Records tie every step to a person, a date, and a lot number. Complaint handling closes the loop with investigation and corrective action.
Those nine areas are the honest answer to what adipose tissue bank quality assurance involves. Our explainer on current good tissue practice unpacks each control, and the chain of custody walkthrough follows one sample through the sequence.
Layer Three: Release Testing Applies to the Lot, Not the Building
A registered facility with a functioning quality system can still produce one bad lot. Release testing exists for that reason, and it attaches to the individual lot rather than to the establishment.
A published specification makes this concrete. Phermthai and colleagues describe a bank release specification requiring endotoxin below 0.5 EU/mL by kinetic turbidimetric LAL, mycoplasma negative by PCR, and sterility by the USP chapter 71 direct method with no growth. Three methods, three thresholds, three pass or fail results, all tied to that lot number. Sterility testing under USP chapter 71 is the compendial standard and is tied to 21 CFR 610.12.
The Timing Problem Almost Nobody Explains
This is where the schedule stops cooperating. Compendial sterility requires a 14 day incubation, and conventional mycoplasma culture requires at least 28 days. A fresh, non-cryopreserved cell product has a shelf life of roughly 48 to 72 hours, as Guadix and colleagues set out in 2019.
Do the arithmetic. A fresh product expires long before its own sterility test finishes, which means it can be administered before the final result exists, unless the facility uses validated rapid methods. Cryopreserved banked tissue does not face that conflict. Frozen material waits in storage while the full incubation runs, so testing finishes before anything is released. That is a structural difference between same-day processing and banking, and it concerns testing logistics only, not whether either product works.
Layer Four: Accreditation Moved From Optional to Legally Required
Accreditation used to be a voluntary mark of quality that nobody could compel. Between 2025 and 2026, three states wrote accrediting organizations into statute by name, turning that credential into a legal precondition for supplying physicians there. This is the newest layer, and the one changing fastest.
Florida’s law, effective July 1, 2025, imposes three cumulative facility requirements: the product must be retrieved, manufactured, and stored in an FDA registered and regulated facility; that facility must be certified or accredited by the National Marrow Donor Program, the World Marrow Donor Association, the Association for the Advancement of Blood and Biotherapies, or the American Association of Tissue Banks; and the lot must contain viable or live cells on post-thaw analysis. The Florida statute text also requires supply contracts to disclose the certifying organization, the scope and dates of that certification, and 30-day notice of any change. Florida sets no numeric viability threshold, a detail our post-thaw viability reporting piece addresses.
Georgia’s Act 453, effective July 1, 2026, accepts an FDA registered facility in Georgia, another state, or another country, or a facility certified or accredited by WMDA, AABB, AATB, or another entity the Department of Public Health deems appropriate. The Georgia legislation requires 30-day notice of any accreditation change, and separately exempts physicians under contract with an institution accredited by FACT, the BMT CTN, or AABB.
Tennessee’s Public Chapter 1016, also effective July 1, 2026, names the American Association of Tissue Banks, the American Academy of Stem Cell Medicine, AABB, FACT, and the World Marrow Donor Program in its regenerative medicine product standards. Tennessee is the only state with numeric viability thresholds, requiring greater than 90 percent on a pre-thaw certificate of analysis and no less than 80 percent on a post-thaw viability analysis report, unless the product is autologous.
Where Save My Fat Sits in All of This
Save My Fat is a connector. It links patients and providers to a United States tissue bank, L2 Bio, and it does not collect, process, store, or test tissue itself. Every layer above is the bank’s obligation, performed at the bank, documented in the bank’s own records.
That changes who you ask for what. A connector can tell you which facility handles your sample and which standards it operates under. Only the bank can hand over the certificate of analysis for your lot or its current accreditation certificate. Adipose tissue and stromal vascular fraction remain investigational, are not FDA approved, and banking does not create access to any treatment pathway.
Frequently Asked Questions
What specific steps does a tissue bank take to validate regulatory compliance?
Four, in sequence. It registers the establishment and lists its HCT/Ps with FDA under 21 CFR Part 1271. It operates a Current Good Tissue Practice quality system under Subpart D. It tests each lot against a written release specification before distribution. It maintains third-party accreditation. Each step generates records, and each record can be requested.
How often are compliance checks performed?
There is no single interval. Storage temperature monitoring runs continuously. Sterility, endotoxin, and mycoplasma testing runs per lot. Equipment calibration and staff training follow schedules set in the bank’s own written procedures. Accreditation certificates carry effective and expiration dates, and Florida and Georgia both require notice within 30 days of a change in accreditation status.
What documentation does a compliant tissue bank maintain?
Standard operating procedures, donor eligibility screening and testing records, environmental monitoring data, equipment calibration logs, reagent traceability, process validation records, labeling controls, storage temperature records, deviation and complaint files, and lot-specific certificates of analysis. Florida additionally requires supply contracts to disclose the accrediting organization, the scope of certification, and its effective and expiration dates.
How can patients verify a bank is actually following these standards?
Ask for documents rather than assurances. Request the FDA registration and listing record, the current accreditation certificate with its scope and expiration, and the certificate of analysis for the specific lot. Registration is a filing rather than approval, so treat it as a starting point, and let a licensed physician help interpret what comes back.
What happens if a compliance validation step is skipped?
Consequences scale with the step. A missed environmental monitoring reading triggers an internal deviation and investigation. A lot released without a passing sterility result is a patient safety failure. In Florida, Georgia, and Tennessee, missing facility documentation can also place the treating physician out of compliance with state law, apart from any federal issue.
Does FDA registration mean the product itself is FDA approved?
No. Registration and listing tell FDA that an establishment exists and what it handles. FDA does not review or approve a product as part of that filing, and it carries no finding of safety or effectiveness. Adipose-derived products remain investigational and are not FDA approved. Any facility calling registration approval is describing it incorrectly.
Key Takeaways
Compliance at a tissue bank is four layers, not one claim. Registration and listing under 21 CFR Part 1271 put a facility on the federal map and nothing more, because registration is not approval. Current Good Tissue Practice under Subpart D supplies the working quality system across donor eligibility, facilities and environmental control, equipment, supplies and reagents, process controls, labeling, storage, records, and complaint handling.
Release testing attaches to the individual lot, with one published specification requiring endotoxin below 0.5 EU/mL by kinetic turbidimetric LAL, mycoplasma negative by PCR, and sterility by the USP chapter 71 direct method with no growth. Timing matters, since a 14 day sterility incubation outlasts a 48 to 72 hour fresh product while cryopreserved material can wait for results. Accreditation is the newest layer, because Florida, Georgia, and Tennessee now name AATB, AABB, WMDA, NMDP, and FACT in statute. Ask for documents. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Patients comparing preservation programs can review current pricing, and documentation questions go to our contact page.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about banking, treatment, or research participation.
About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.
Related guide: FDA adipose tissue regulation.
